4.4 Review

Cannabidiol: pharmacology and therapeutic targets

期刊

PSYCHOPHARMACOLOGY
卷 238, 期 1, 页码 9-28

出版社

SPRINGER
DOI: 10.1007/s00213-020-05712-8

关键词

Cannabidiol; Cannabis; Human; Pharmacokinetics; Medical cannabis; Marijuana

资金

  1. National Institute on Drug Abuse [R21 DA045101, R01 DA045700, R01 DA016718, R01 DA040637, T32 DA035200]

向作者/读者索取更多资源

CBD products are commonly used for self-treatment without regulatory approval, with limited scientific evidence from clinical trials. Epidiolex is the only rigorously evaluated product approved for intractable childhood-onset seizures, while studies on CBD for other medical conditions are limited in number and often lack scientific rigor.
Rationale Cannabidiol (CBD) products lacking regulatory approval are being used to self-treat a myriad of conditions and for their unsubstantiated health benefits. The scientific evidence supporting these claims largely arises not from controlled clinical trials, but from the recognition that CBD has numerous biological targets. Yet, CBD is commonly consumed and often in over-the-counter products that are unapproved and of unknown composition. Epidiolex (R) is the only product that has undergone rigorous pharmacokinetic assessment and testing in clinical trials; it was approved as a non-scheduled drug by the U.S. Food and Drug Administration for the treatment of intractable childhood-onset seizures. However, studies investigating CBD for other medical conditions are limited in number and often lack the scientific rigor, controls, or sample sizes required to draw clinically meaningful conclusions. Although Epidiolex (R) is safe for human consumption, recent changes in regulation of commercially available CBD products have resulted in limited quality control and products marketed with unknown CBD bioavailability. Even scientifically rigorous studies have used different sources of CBD and different suspension vehicles for administration, making it difficult to compare results among studies and resolve mixed outcomes. Objectives This paper reviews the molecular targets, pharmacokinetics, and safety and abuse liability of CBD; additionally, the extant evidence on its potential therapeutic effects for neurological disorders, pain, inflammation, conditions related to immune function, psychiatric disorders, and substance use are described.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据